{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:21:15Z","timestamp":1781788875105,"version":"3.54.5"},"reference-count":22,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006530","name":"council on graduate medical education, new york state department of health","doi-asserted-by":"publisher","award":["Research and Education Foundation Research Grant"],"award-info":[{"award-number":["Research and Education Foundation Research Grant"]}],"id":[{"id":"10.13039\/100006530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,8]]},"abstract":"\n Background:<\/jats:title>\n \n Vancomycin guidelines by the Infectious Diseases Society of America and American Society of Health-System Pharmacists endorse Bayesian-software-assisted area under the curve (AUC\n 24h<\/jats:sub>\n ) in their 2020 update. At this time, there are limited clinical data that support its use.\n <\/jats:p>\n <\/jats:sec>\n \n Objectives:<\/jats:title>\n \n The purpose of this study is to evaluate the safety benefits and efficacy outcomes of using Bayesian-assisted AUC\n 24h<\/jats:sub>\n dosing compared to trough dosing.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n Hospitalized patients from before February 1, 2020, (preimplementation of AUC\n 24h<\/jats:sub>\n dosing) and after August 1, 2020, (postimplementation) were reviewed. Patients with confirmed or suspected methicillin-resistant\n Staphylococcus aureus<\/jats:italic>\n (MRSA) infection of the lungs, heart, bones, prosthetic joint, or blood receiving vancomycin for at least 72 hours were included. The primary endpoint was the percentage of patients experiencing an acute kidney injury (AKI) in the trough-based group versus those experiencing AKI in the AUC\n 24h<\/jats:sub>\n group. The composite of all-cause mortality, 30-day readmission, or change in antibiotic therapy due to clinical worsening in patients with confirmed MRSA infections was included as a secondary endpoint. Data were analyzed with statistical testing methods as appropriate.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n There was a significant reduction in AKI between the AUC\n 24h<\/jats:sub>\n dosing and trough dosing groups (3% vs 12%;\n P<\/jats:italic>\n < 0.01). The efficacy for MRSA infections was also similar between groups (11% vs 14%;\n P<\/jats:italic>\n = 0.72).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance:<\/jats:title>\n \n Bayesian-assisted AUC\n 24h<\/jats:sub>\n dosing was associated with a significant reduction in incidence of AKI when compared to trough-based dosing. There was no difference in the composite efficacy endpoint for patients with confirmed MRSA infection, although the study was not powered for this analysis. These data may provide evidence for more institutions to adopt the Bayesian software to assist in dosing of vancomycin.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10600280221141402","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T08:17:22Z","timestamp":1670487442000},"page":"931-939","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Vancomycin Bayesian-Estimated Area Under the Curve Versus Trough-Based Dosing"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1038-3362","authenticated-orcid":false,"given":"John","family":"Cerenzio","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Brooklyn Hospital Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-2852","authenticated-orcid":false,"given":"James","family":"Truong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Brooklyn Hospital Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Vancomycin package insert. Bangalore India: Mylan Laboratories; 2018."},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control and Prevention. Antibiotic\/antimicrobial resistance. Published July 2020. Accessed August 20 2020. https:\/\/www.cdc.gov\/antibiotic-use\/."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-12."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz460."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03970-14."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000343162."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz051."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/b:jopa.0000029490.76908.0c."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02042-17."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019897100."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp085."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02478-16."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339789."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1995.tb04335.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318289ff1e."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4.947."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.014."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.12.013."},{"key":"e_1_3_2_23_2","volume-title":"Performance standards of antimicrobial susceptibility testing","author":"CLSI","year":"2020","unstructured":"CLSI. Performance standards of antimicrobial susceptibility testing. 30th ed. CLSI M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.","edition":"30"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221141402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221141402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221141402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:57Z","timestamp":1777374777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221141402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1177\/10600280221141402"],"URL":"https:\/\/doi.org\/10.1177\/10600280221141402","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}